FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Efx第一季度业绩超预期:抵押贷款激增推动营收增长14%,创新加速

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:EFX第一季度业绩强劲,调整后每股收益为1.86美元,高于去年同期的1.53美元,超出市场预期0.16美元。营收达16.5亿美元(增长14%),超出预期3700万美元,超出市场预期3000万美元,这主要得益于伊朗冲突影响利率之前,1月至2月美国抵押贷款业务实现了38%的惊人增长。各业务板块均展现出强劲的运营实力,其中USIS业务增长21%(远高于6%-8%的预期),这得益于抵押贷款业务60%的增长以及多元化市场业务的稳定表现。创新势头加速,活力指数达到创纪录的17%,高于10%的目标值,这反映了EFX在近30亿美元的技术投资基础上,成功部署了云和人工智能平台。强劲的现金流为股东带来了 3.27 亿美元的回报,其中包括 2.6 亿美元的股票回购和 6700 万美元的股息;同时,1.215 亿美元的自由现金流支持了持续的云转型投资,我们认为,随着各项举措获得市场认可,这些投资应该会推动持续增长。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703